Glenmark to divest majority stake in Glenmark Life Sciences to Nirma
Nirma will acquire 75 per cent stake in Glenmark Life Sciences at a price of Rs 615/- per share
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
definitive agreement
Baxter to divest biopharma solutions business to Advent International and Warburg Pincus for $4.25…
Net proceeds planned to be redeployed for debt repayment in accordance with Baxter’s stated capital allocation priorities
Fermenta Biotech licenses its proprietary enzymatic technology for manufacturing Molnupiravir to…
Fermenta has signed a definitive agreement with Aurigene, a stepdown subsidiary of Dr Reddy’s Laboratories